Critical illness-induced dysglycaemia : diabetes and beyond by Smith, F. Gao (Fang Gao) et al.
 University of Warwick institutional repository: http://go.warwick.ac.uk/wrap 
 
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
Author(s):  Fang G Smith, Ann M Sheehy, Jean-Louis Vincent and 
Douglas B Coursin 
Article Title: Critical illness-induced dysglycaemia: diabetes and 
beyond 
Year of publication: 2011 
Link to published article:  
http://dx.doi.org/10.1186/cc9266 
Publisher statement: None 
 
Type 2 diabetes is one of the greatest challenges facing 
health care professionals. Th e general population disease 
prevalence is approximately 2.8% worldwide [1]. In con-
trast, the most recent US National Health and Nutrition 
Examination Survey estimates that 12.9% of US ambula-
tory adults over 20 years of age have type 2 diabetes [2]. 
Th e prevalence of diabetes is expected to double over the 
next 30 years due to increased age, inactivity and obesity [1].
Complicating this phenomenon is the knowledge that 
approximately 40% of patients with diabetes remain 
undiagnosed [2]. Th ese patients cannot be treated, and 
are vulnerable to short-term and long-term complications 
[3-5]. Th e true prevalence of diabetes in hospitalised 
patients is not known, due to the heterogeneous patient 
population and limitations in diagnostic tests [6]. Th e 
prevalence in intensive care unit (ICU) patients is 
perhaps 25% or higher, depending on unit specialty and 
patient demographics [6].
Adults with diabetes have at least double the annual 
mortality compared with adults without diabetes [7]. 
Paradoxically, several studies of hospitalised patients 
have demonstrated that hyperglycaemic individuals with-
out known diabetes have signiﬁ cantly greater morbidity 
and mortality than either patients with known diabetes 
or those with normal glucose tolerance [8-11]. Hyper-
glycaemic patients without diabetes include those with 
undiagnosed diabetes, prediabetes (impaired fasting 
glucose and impaired glucose tolerance) or stress-
induced hyperglycaemia (SIH) – deﬁ ned as patients with 
elevated blood glucose that reverts to normal after illness 
subsides and counterregulatory hormone and inﬂ amma-
tory mediator surge abates [6]. Large, retrospective 
studies in critically ill adults have shown that hyper-
glycaemic patients with diabetes have lower ICU and 
hospital mortality and shorter length of ICU stay than 
critically ill hyperglycaemic patients without diabetes 
[8-10]. Th is increased mortality in hyperglycaemic 
patients without diabetes occurs despite this population 
having lower absolute glucose levels than those with 
diabetes. Similar ﬁ ndings were reported in hospitalised 
general care patients [11].
How can this paradox be explained? First, patients 
without diabetes may have unexpected hyperglycaemia 
that is frequently left untreated. Umpierrez and 
colleagues showed that insulin therapy was provided to 
77% of patients with known diabetes, compared with 35% 
of hyperglycaemic patients without diabetes [11]. Second, 
the critically ill nondiabetic hyperglycaemic population 
comprises patients with undiagnosed diabetes and 
patients with SIH [6,12]. Whether hyperglycaemia and 
adverse outcomes in the nondiabetic cohort are due to 
SIH, or are simply a marker of severity of illness, remains 
unknown. Prospective studies with clearly deﬁ ned 
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nondiabetic cohorts are needed to diﬀ erentiate between 
undiagnosed diabetes and SIH.
Accurately diagnosing hyperglycaemic ICU patients 
with new diabetes while they are still hospitalised, how-
ever, remains diﬃ  cult. Fasting plasma glucose values and 
oral glucose tolerance tests can only be used in ICU 
survivors after discharge, as these tests are inaccu rate 
during critical illness [6,12]. Recently endorsed by the 
Inter national Expert Committee [13] and the American 
Diabetes Association as a diagnostic criterion for 
diabetes mellitus [14], haemoglobin A1c may prove useful 
in categorising inpatients [15]. But haemoglobin A1c must 
be used carefully, as it may be inaccurate in conditions 
that shorten or prolong the survival of erythrocytes and 
in patients receiving blood transfusions [13]. Likewise, its 
value may vary by racial or ethnic group [16]. Ambulatory 
follow-up at 6 to 8 weeks post recovery aﬀ ords the best 
opportunity to look back and diagnose type 2 diabetes 
[12].
Owing to these limitations, few studies have attempted 
to deﬁ ne the true prevalence of diabetes in ICU patients 
with unexpected inpatient hyperglycaemia. Recently, 
Mullhi and colleagues showed in ICU survivors (n = 30) 
with new hyperglycaemia that 46.7% (n = 14) had undiag-
nosed diabetes and 30% had a prediabetes state (n = 9 
impaired fasting glycaemia or glucose tolerance) during 
their ICU stay [17]. Similarly, the natural history of ICU 
patients with inpatient hyperglycaemia but without 
diabetes merits further study. Gornik and colleagues 
recently reported that 15.2% of septic ICU patients with 
documented SIH and normal, post-discharge glucose 
tolerance developed diabetes within 5 years of hospital 
discharge, versus 4.2% of normoglycaemic ICU patients 
[18]. Th e authors hypo the sised that stress may uncover 
latent metabolic disturbance. Gornik and colleagues 
presented very similar ﬁ ndings in Critical Care about the 
development of type 2 diabetes in 17.1% of patients with 
SIH among nearly 600 heterogeneous critically ill 
patients followed for 5 years after ICU discharge [19]. 
Th ese longitudinal data reveal the importance of 
continued surveillance of this high-risk population.
Inpatients may also experience other types of glucose 
dysregulation. Large, randomised controlled trials from 
the past decade, which investigated the impact of 
preventing pronounced hyperglycaemia during critical 
illness with insulin infusion, report increased mortality 
associated with hypoglycaemia [20-23]. Egi and 
colleagues showed that increased mortality in mildly 
hypoglycaemic patients (blood glucose <80 mg/dl) may 
be independent of insulin use [21]. Th eir ﬁ ndings suggest 
that altered glucose metabolism, as well as exogenous 
overtreatment with insulin, may play a meaningful role in 
critical illness and mortality. In a retrospective cohort 
analysis of 7,820 patients with acute myocardial infarc-
tion, Kosiborod and colleagues reported that patients 
who developed spontaneous hypoglycaemia had an 
increased mortality while those who developed it 
secondary to insulin therapy did not [24]. Several studies 
have also demonstrated increased mortality with either 
hypo glycaemia or hyperglycaemia [20,21]. Glucose varia-
bility may confer an adverse risk of mortality, indepen-
dent of absolute glucose level [23] – although recently the 
Leuven group retrospectively analysed their two large 
prospective glucose control trials, and determined that 
the reduced mortality observed with intensive insulin 
therapy in the trials was not attributable to an eﬀ ect on 
blood glucose variability [25]. Th e accompanying editorial 
by Krinsley, however, raised additional factors such as 
frequency of hypoglycaemia and method of glucose 
measurement that may have inﬂ uenced these ﬁ ndings 
[26]. Limitations in existing glucose monitoring tech-
nology further complicate the above issues. Th is diﬃ  culty 
cannot be ignored when applying protocols to control 
and regulate blood glucose [27]. 
We suggest a broader view of glucose dysregulation in 
the critically ill patient based on numerous factors 
(Table  1). We apply the term critical illness-induced 
dysglycaemia to patients with hyperglycaemia, hypo gly-
caemia or glucose variability. Patients without diabetes, 
but with other features of critical illness-induced 
dysglycaemia, appear to be at risk to develop overt type 2 
diabetes. Th ese patients should undergo longi tudinal 
evaluation and intervention for the develop ment of 
subsequent type 2 diabetes.
Th e decade ending in 2009 witnessed an explosion in 
publications about ICU glycaemic control, beginning 
Table 1. Factors impacting critical illness-induced dysglycaemia
Continued growth of abnormal glucose homeostasis in adults 
Heterogeneous intensive care unit patient population 
Uncertainty as to whether hyperglycaemia may cause adverse outcomes, or may simply be the eff ect of counterregulatory hormone surge indicating severity 
of illness 
Need for further clarifi cation of the incidence of co-existing factors in the development of and role of hypoglycaemia (<80 mg/dl) on intensive care unit 
outcome
Ongoing debate over the ideal method and frequency of glucose measurement, the optimal glucose level to maintain in adult intensive care unit populations, 
and the modulation of glucose variability
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with the landmark Leuven trial in 2001 [28]. Formal 
recom mendations in 2004 endorsed tight glycaemic 
control [29]. Th e decade ended with the 2009 publication 
of the NICE-SUGAR study [22], and less stringent critical 
care glucose control guidelines [30]. Th e concept of 
critical illness-induced dysglycaemia encompasses all of 
these factors. We issue a call to recognise the hetero-
geneous inpatient hypoglycaemic or hyperglycaemic 
popu lation, in order to study hyperglycaemic subpopu-
lations, to determine diagnostic alternatives for diagnosis 
of unrecognised inpatients with diabetes, and to develop 
better monitoring and application of safe, closed-loop 
systems. 
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